Fecal Microbial Composition and Predicted Functional Profile in Irritable Bowel Syndrome Differ between Subtypes and Geographical Locations

Jose F Garcia-Mazcorro; Mercedes Amieva-Balmori; Arturo Triana-Romero; Bridgette Wilson; Leanne Smith; Job Reyes-Huerta; Megan Rossi; Kevin Whelan; Jose M Remes-Troche

doi:10.3390/microorganisms11102493

Fecal Microbial Composition and Predicted Functional Profile in Irritable Bowel Syndrome Differ between Subtypes and Geographical Locations

Jose F Garcia-Mazcorro, Mercedes Amieva-Balmori, Arturo Triana-Romero, Bridgette Wilson, Leanne Smith, Job Reyes-Huerta, Megan Rossi, Kevin Whelan, Jose M Remes-Troche

Nutritional Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Increasing evidence suggests a microbial pathogenesis in irritable bowel syndrome (IBS) but the relationship remains elusive. Fecal DNA samples from 120 patients with IBS, 82 Mexican (IBS-C: n = 33, IBS-D: n = 24, IBS-M: n = 25) and 38 British (IBS-C: n = 6, IBS-D: n = 27, IBS-M: n = 5), were available for analysis using 16S rRNA gene sequencing. Firmicutes (mean: 82.1%), Actinobacteria (10.2%), and Bacteroidetes (4.4%) were the most abundant taxa. The analysis of all samples (n = 120), and females (n = 94) only, showed no significant differences in bacterial microbiota, but the analysis of Mexican patients (n = 82) showed several differences in key taxa (e.g., Faecalibacterium) among the different IBS subtypes. In IBS-D there were significantly higher Bacteroidetes in British patients (n = 27) than in Mexican patients (n = 24), suggesting unique fecal microbiota signatures within the same IBS subtype. These differences in IBS-D were also observed at lower phylogenetic levels (e.g., higher Enterobacteriaceae and Streptococcus in Mexican patients) and were accompanied by differences in several alpha diversity metrics. Beta diversity was not different among IBS subtypes when using all samples, but the analysis of IBS-D patients revealed consistent differences between Mexican and British patients. This study suggests that fecal microbiota is different between IBS subtypes and also within each subtype depending on geographical location.

Original language	English
Article number	2493
Journal	Microorganisms
Volume	11
Issue number	10
DOIs	https://doi.org/10.3390/microorganisms11102493
Publication status	Published - 5 Oct 2023

Access to Document

10.3390/microorganisms11102493Licence: CC BY

Cite this

Garcia-Mazcorro, J. F., Amieva-Balmori, M., Triana-Romero, A., Wilson, B., Smith, L., Reyes-Huerta, J., Rossi, M., Whelan, K., & Remes-Troche, J. M. (2023). Fecal Microbial Composition and Predicted Functional Profile in Irritable Bowel Syndrome Differ between Subtypes and Geographical Locations. Microorganisms, 11(10), Article 2493. https://doi.org/10.3390/microorganisms11102493

@article{3062fae8141b47f0885e67cc1f22b6f6,

title = "Fecal Microbial Composition and Predicted Functional Profile in Irritable Bowel Syndrome Differ between Subtypes and Geographical Locations",

abstract = "Increasing evidence suggests a microbial pathogenesis in irritable bowel syndrome (IBS) but the relationship remains elusive. Fecal DNA samples from 120 patients with IBS, 82 Mexican (IBS-C: n = 33, IBS-D: n = 24, IBS-M: n = 25) and 38 British (IBS-C: n = 6, IBS-D: n = 27, IBS-M: n = 5), were available for analysis using 16S rRNA gene sequencing. Firmicutes (mean: 82.1%), Actinobacteria (10.2%), and Bacteroidetes (4.4%) were the most abundant taxa. The analysis of all samples (n = 120), and females (n = 94) only, showed no significant differences in bacterial microbiota, but the analysis of Mexican patients (n = 82) showed several differences in key taxa (e.g., Faecalibacterium) among the different IBS subtypes. In IBS-D there were significantly higher Bacteroidetes in British patients (n = 27) than in Mexican patients (n = 24), suggesting unique fecal microbiota signatures within the same IBS subtype. These differences in IBS-D were also observed at lower phylogenetic levels (e.g., higher Enterobacteriaceae and Streptococcus in Mexican patients) and were accompanied by differences in several alpha diversity metrics. Beta diversity was not different among IBS subtypes when using all samples, but the analysis of IBS-D patients revealed consistent differences between Mexican and British patients. This study suggests that fecal microbiota is different between IBS subtypes and also within each subtype depending on geographical location.",

author = "Garcia-Mazcorro, {Jose F} and Mercedes Amieva-Balmori and Arturo Triana-Romero and Bridgette Wilson and Leanne Smith and Job Reyes-Huerta and Megan Rossi and Kevin Whelan and Remes-Troche, {Jose M}",

note = "Funding Information: This research was funded by the Newton Fund (grant MR/N029097/1) from the Medical Research Council (UK) and CONACYT (FONCYCIT, 1000-830-2016, Mexico). The APC received no external funding. Funding Information: B.W. was supported by a doctoral research grant from Clasado Biosciences Ltd. and is the coinventor of volatile organic compounds in the diagnosis and dietary management of IBS. M.R. has received funding from the Almond Board of California, Danone, and the International Nut and Dried Fruit Council, is the coinventor of volatile organic compounds in the diagnosis and dietary management of IBS, and is co-founder of Bio&Me, a gut health food brand. K.W. has served as a consultant for Danone, has received speaker{\textquoteright}s fees from Alpro and Yakult and research funding from Clasado Biosciences, Nestec Ltd., the Almond Board of California, and the International Nut and Dried Fruit Council, and is a coinventor of volatile organic compounds in the diagnosis and management of IBS. J.M.R.T. has served as a consultant for Takeda, Biocodex, Asofarma, Carnot, Medtronic, and Alfasigma, and has received speaker{\textquoteright}s fees, travel support, and participated in medical board meetings with Takeda Mexico, Asofarma, Carnot, Medix, Bayer, and Alfasigma. M.A.B has received speaker{\textquoteright}s fees from Carnot. The remaining authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = oct,

day = "5",

doi = "10.3390/microorganisms11102493",

language = "English",

volume = "11",

journal = "Microorganisms",

issn = "2076-2607",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "10",

}

TY - JOUR

T1 - Fecal Microbial Composition and Predicted Functional Profile in Irritable Bowel Syndrome Differ between Subtypes and Geographical Locations

AU - Garcia-Mazcorro, Jose F

AU - Amieva-Balmori, Mercedes

AU - Triana-Romero, Arturo

AU - Wilson, Bridgette

AU - Smith, Leanne

AU - Reyes-Huerta, Job

AU - Rossi, Megan

AU - Whelan, Kevin

AU - Remes-Troche, Jose M

N1 - Funding Information: This research was funded by the Newton Fund (grant MR/N029097/1) from the Medical Research Council (UK) and CONACYT (FONCYCIT, 1000-830-2016, Mexico). The APC received no external funding. Funding Information: B.W. was supported by a doctoral research grant from Clasado Biosciences Ltd. and is the coinventor of volatile organic compounds in the diagnosis and dietary management of IBS. M.R. has received funding from the Almond Board of California, Danone, and the International Nut and Dried Fruit Council, is the coinventor of volatile organic compounds in the diagnosis and dietary management of IBS, and is co-founder of Bio&Me, a gut health food brand. K.W. has served as a consultant for Danone, has received speaker’s fees from Alpro and Yakult and research funding from Clasado Biosciences, Nestec Ltd., the Almond Board of California, and the International Nut and Dried Fruit Council, and is a coinventor of volatile organic compounds in the diagnosis and management of IBS. J.M.R.T. has served as a consultant for Takeda, Biocodex, Asofarma, Carnot, Medtronic, and Alfasigma, and has received speaker’s fees, travel support, and participated in medical board meetings with Takeda Mexico, Asofarma, Carnot, Medix, Bayer, and Alfasigma. M.A.B has received speaker’s fees from Carnot. The remaining authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. Publisher Copyright: © 2023 by the authors.

PY - 2023/10/5

Y1 - 2023/10/5

N2 - Increasing evidence suggests a microbial pathogenesis in irritable bowel syndrome (IBS) but the relationship remains elusive. Fecal DNA samples from 120 patients with IBS, 82 Mexican (IBS-C: n = 33, IBS-D: n = 24, IBS-M: n = 25) and 38 British (IBS-C: n = 6, IBS-D: n = 27, IBS-M: n = 5), were available for analysis using 16S rRNA gene sequencing. Firmicutes (mean: 82.1%), Actinobacteria (10.2%), and Bacteroidetes (4.4%) were the most abundant taxa. The analysis of all samples (n = 120), and females (n = 94) only, showed no significant differences in bacterial microbiota, but the analysis of Mexican patients (n = 82) showed several differences in key taxa (e.g., Faecalibacterium) among the different IBS subtypes. In IBS-D there were significantly higher Bacteroidetes in British patients (n = 27) than in Mexican patients (n = 24), suggesting unique fecal microbiota signatures within the same IBS subtype. These differences in IBS-D were also observed at lower phylogenetic levels (e.g., higher Enterobacteriaceae and Streptococcus in Mexican patients) and were accompanied by differences in several alpha diversity metrics. Beta diversity was not different among IBS subtypes when using all samples, but the analysis of IBS-D patients revealed consistent differences between Mexican and British patients. This study suggests that fecal microbiota is different between IBS subtypes and also within each subtype depending on geographical location.

AB - Increasing evidence suggests a microbial pathogenesis in irritable bowel syndrome (IBS) but the relationship remains elusive. Fecal DNA samples from 120 patients with IBS, 82 Mexican (IBS-C: n = 33, IBS-D: n = 24, IBS-M: n = 25) and 38 British (IBS-C: n = 6, IBS-D: n = 27, IBS-M: n = 5), were available for analysis using 16S rRNA gene sequencing. Firmicutes (mean: 82.1%), Actinobacteria (10.2%), and Bacteroidetes (4.4%) were the most abundant taxa. The analysis of all samples (n = 120), and females (n = 94) only, showed no significant differences in bacterial microbiota, but the analysis of Mexican patients (n = 82) showed several differences in key taxa (e.g., Faecalibacterium) among the different IBS subtypes. In IBS-D there were significantly higher Bacteroidetes in British patients (n = 27) than in Mexican patients (n = 24), suggesting unique fecal microbiota signatures within the same IBS subtype. These differences in IBS-D were also observed at lower phylogenetic levels (e.g., higher Enterobacteriaceae and Streptococcus in Mexican patients) and were accompanied by differences in several alpha diversity metrics. Beta diversity was not different among IBS subtypes when using all samples, but the analysis of IBS-D patients revealed consistent differences between Mexican and British patients. This study suggests that fecal microbiota is different between IBS subtypes and also within each subtype depending on geographical location.

UR - http://www.scopus.com/inward/record.url?scp=85175083393&partnerID=8YFLogxK

U2 - 10.3390/microorganisms11102493

DO - 10.3390/microorganisms11102493

M3 - Article

C2 - 37894151

SN - 2076-2607

VL - 11

JO - Microorganisms

JF - Microorganisms

IS - 10

M1 - 2493

ER -

Fecal Microbial Composition and Predicted Functional Profile in Irritable Bowel Syndrome Differ between Subtypes and Geographical Locations

Abstract

Access to Document

Other files and links

Fingerprint

Cite this